Reference
Oh I-J, et al. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma. Clinical Lung Cancer 19: e775-e781, No. 5, Sep 2018. Available from: URL: http://doi.org/10.1016/j.cllc.2018.05.018 - South Korea
Rights and permissions
About this article
Cite this article
Afatinib/poziotinib. Reactions Weekly 1721, 17 (2018). https://doi.org/10.1007/s40278-018-52054-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-52054-1